STIM - Neuronetics Inc

STIM - Neuronetics Inc

https://neurostar.com

Buy Momentum: Bearish

Recent News

Powered by Alpha Vantage

Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635 ( c ) ( 4 ) - Neuronetics ( NASDAQ:STIM )

Benzinga • 1 month, 1 week ago • score: 0.04

MALVERN, Pa., Aug. 06, 2025 ( GLOBE NEWSWIRE ) -- Neuronetics, Inc. STIM, a commercial stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, today announced the granting of ...

Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635 ( c ) ( 4 )

GlobeNewswire • 1 month, 1 week ago • score: 0.04

MALVERN, Pa., Aug. 06, 2025 ( GLOBE NEWSWIRE ) -- Neuronetics, Inc. ( NASDAQ: STIM ) , a commercial stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, today announced the ...

Neuronetics ( STIM ) Reports Q2 Loss, Tops Revenue Estimates

Zacks Commentary • 1 month, 1 week ago • score: 0.13

Neuronetics (STIM) delivered earnings and revenue surprises of -87.50% and +3.87%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Neuronetics to Present at the Canaccord Genuity 45th Annual Growth Conference

GlobeNewswire • 1 month, 1 week ago • score: -0.05

MALVERN, Pa., Aug. 04, 2025 ( GLOBE NEWSWIRE ) -- Neuronetics, Inc. ( NASDAQ: STIM ) , a vertically integrated, commercial stage, medical technology and healthcare company with a strategic vision of transforming the lives of patients whenever and wherever they need help, with the leading ...

Neuronetics to Report Second Quarter 2025 Financial and Operating Results and Host Conference Call - Neuronetics ( NASDAQ:STIM )

Benzinga • 1 month, 3 weeks ago • score: 0.07

MALVERN, Pa., July 22, 2025 ( GLOBE NEWSWIRE ) -- Neuronetics, Inc.

Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635 ( c ) ( 4 )

GlobeNewswire • 2 months, 3 weeks ago • score: 0.04

MALVERN, Pa., June 19, 2025 ( GLOBE NEWSWIRE ) -- Neuronetics, Inc. ( NASDAQ: STIM ) , a commercial stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, today announced the ...

Interval:

EMA1: EMA2:

AI Tools

Key Metrics

Trend: Range-Bound

As of 2025-09-10 (Snapshot)

Neuronetics, Inc., a commercial-stage medical technology company, designs, develops, and markets products for patients with psychiatric disorders in the United States and internationally. The company is headquartered in Malvern, Pennsylvania.

52W High

$5.92

52W Low

$0.52

MA Status:

50D: Below 200D: Above

Beta (~1 neutral, <0.9 lower risk)

1.28

Valuation

As of 2025-06-30 (Overview)

Trailing P/E (<15 better)

N/A

Forward P/E (<15 better)

N/A

EV/EBITDA (<8 favorable)

-2.02

EV/Revenue (<3 favorable)

2.55

P/S (TTM) (<3 favorable)

1.92

P/B (<3 favorable)

7.87

Ownership

Balanced

Source: Overview

Insiders (1–5% typical)

9.44%

Institutions (25–75% balanced)

59.08%

Shares Outstanding

66,125,000

Float

40,965,600

Dividend Yield (2–6% sweet spot)

N/A

Ex‑Dividend Date

N/A

Income & Growth

Profitability: Weak

As of 2025-06-30 (Overview)

Revenue (TTM)

111,106,000

Gross Profit (TTM)

62,990,000

EPS (TTM)

-1.15

Profit Margin (>10% good)

-0.44%

Operating Margin (TTM) (higher better)

-0.21%

ROE (TTM) (>15% strong)

-1.91%

EPS YoY (Quarterly) (>10% good)

N/A

Revenue YoY (Quarterly) (>8% good)

1.32

Momentum

Bearish momentum

Value

-0.1349

Previous

-0.1115

Trend

Falling

Signal Cross

No cross

As of

Sep. 12, 2025